Cytokinetics, IncorporatedCytokinetics, IncorporatedCytokinetics, Incorporated

Cytokinetics, Incorporated

No trades
See on Supercharts
Market capitalization
‪7.10 B‬USD
−5.45USD
‪−526.24 M‬USD
‪7.53 M‬USD
‪100.93 M‬
Beta (1Y)
0.61

About Cytokinetics, Incorporated

CEO
Robert I. Blum
Headquarters
South San Francisco
Employees (FY)
423
Founded
1997
ISIN
US23282W6057
FIGI
BBG000F0R4N9
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of CYTK is 67.57 USD — it has decreased by 0.53% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cytokinetics, Incorporated stocks are traded under the ticker CYTK.
Cytokinetics, Incorporated is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
CYTK stock is 1.82% volatile and has beta coefficient of 0.61. Check out the list of the most volatile stocks — is Cytokinetics, Incorporated there?
One year price forecast for Cytokinetics, Incorporated has a max estimate of 122.00 USD and a min estimate of 75.00 USD.
CYTK earnings for the last quarter are −1.35 USD whereas the estimation was −0.74 USD which accounts for −81.73% surprise. Estimated earnings for the next quarter are −0.96 USD. See more details about Cytokinetics, Incorporated earnings.
Cytokinetics, Incorporated revenue for the last quarter amounts to ‪378.00 K‬ USD despite the estimated figure of ‪20.24 M‬ USD. In the next quarter revenue is expected to reach ‪7.62 M‬ USD.
Yes, you can track Cytokinetics, Incorporated financials in yearly and quarterly reports right on TradingView.
CYTK stock has fallen by 9.89% compared to the previous week, the month change is a 6.18% rise, over the last year Cytokinetics, Incorporated has showed a 86.30% increase.
CYTK net income for the last quarter is ‪−136.90 M‬ USD, while the quarter before that showed ‪−129.42 M‬ USD of net income which accounts for −5.77% change. Track more Cytokinetics, Incorporated financial stats to get the full picture.
Today Cytokinetics, Incorporated has the market capitalization of ‪7.10 B‬, it has increased by 4.54% over the last week.
No, CYTK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CYTK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cytokinetics, Incorporated stock right from TradingView charts — choose your broker and connect to your account.
CYTK reached its all-time high on Jan 8, 2024 with the price of 110.25 USD, and its all-time low was 3.05 USD and was reached on Oct 13, 2014.
See other stocks reaching their highest and lowest prices.
As of Apr 18, 2024, the company has 423.00 employees. See our rating of the largest employees — is Cytokinetics, Incorporated on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cytokinetics, Incorporated technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cytokinetics, Incorporated stock shows the buy signal. See more of Cytokinetics, Incorporated technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Cytokinetics, Incorporated future price: according to them, CYTK price has a max estimate of 122.00 USD and a min estimate of 75.00 USD. Read a more detailed Cytokinetics, Incorporated forecast: see what analysts think of Cytokinetics, Incorporated and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cytokinetics, Incorporated EBITDA is ‪−482.44 M‬ USD, and current EBITDA margin is ‪−6.43 K‬%. See more stats in Cytokinetics, Incorporated financial statements.